1. Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen
   Nidia Alvarez-Rueda et al, 2007, Clinical Cancer Research CrossRef
2. Immune Environment and Osteosarcoma
   Marie-Françoise Heymann et al, 2017, Osteosarcoma - Biology, Behavior and Mechanisms CrossRef
3. Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database
   Eric Sterner et al, 2016, ACS Chemical Biology CrossRef
4. Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma
   Thorsten Simon et al, 2004, Journal of Clinical Oncology CrossRef
5. Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of α-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2
   Matthias Miederer et al, 2004, Clinical Cancer Research CrossRef
6. T-Cell Chauvinists Versus Antibody Advocates—Can't We All Just Get Along?
   Paul B. Chapman, 2004, Journal of Clinical Oncology CrossRef
7. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
   Ha Gyeong Shin et al, 2022, International Journal of Molecular Sciences CrossRef
8. Monitoring Immune Responses in Neuroblastoma Patients during Therapy
   Celina L. Szanto et al, 2020, Cancers CrossRef
9. Immunotherapy of Neuroblastoma Targeting GD2 and Beyond
   Jung-Tung Hung et al, 2023, Glycosignals in Cancer CrossRef
10. Biology of GD2 ganglioside: implications for cancer immunotherapy
    Pierre Machy et al, 2023, Frontiers in Pharmacology CrossRef
11. Monoclonal Antibody Therapies for High Risk Neuroblastoma
    Wayne L Furman, 2021, Biologics: Targets and Therapy CrossRef
12. Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma
    Brian H. Kushner et al, 2004, Journal of Clinical Oncology CrossRef
13. Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
    Aicha E. Quamine et al, 2021, Cancers CrossRef
14. Phase II Trial of the Anti-GD2Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma
    Brian H. Kushner et al, 2001, Journal of Clinical Oncology CrossRef
15. GD2-targeting therapy: a comparative analysis of approaches and promising directions
    Julia Philippova et al, 2024, Frontiers in Immunology CrossRef
16. Quantitation of GD2 Synthase mRNA by Real-Time Reverse Transcriptase Polymerase Chain Reaction: Clinical Utility in Evaluating Adjuvant Therapy in Neuroblastoma
    Irene Y. Cheung et al, 2003, Journal of Clinical Oncology CrossRef